Bellus Health

Investors & Media

News Release

« Back

BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment


- Professor Jacky Smith from the University of Manchester to lead live webcast -

LAVAL, Quebec--(BUSINESS WIRE)-- BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, 2019 in New York City. The event will include discussions on the unmet medical need in the category, and a review of current therapies in development including P2X3 antagonists. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagonist product candidate for the treatment of chronic cough, BLU-5937.

Dr. Jacky Smith, MB, ChB, FRCP, PhD, is a Professor of Respiratory Medicine at the University of Manchester, UK and an Honorary Consultant at University Hospital of South Manchester NHS Foundation Trust. She runs a multi-disciplinary research team whose focus is on understanding mechanisms underlying pathological cough, and a regional clinical service seeing patients with refractory chronic cough. Her main research interests lie in developing new endpoints in cough monitoring, understanding the mechanisms underlying cough in respiratory diseases and the testing of novel anti-tussive therapies. She is the Principal Investigator of BELLUS Health’s Phase 2 study of BLU-5937 in refractory chronic cough.

Meeting Details:

Event: BELLUS Health Chronic Cough KOL Meeting 
Date: Tuesday, July 16, 2019 
Time: 8:30 a.m.-11:30 a.m. EDT

The live webcast of the event may be accessed through the Events and Presentations page of BELLUS Health’s website, under the Investors & News section. The archived webcast and presentation will be available on the Company’s website after the event.

About BELLUS Health (

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead product candidate, BLU-5937, is being developed for the treatment of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. In addition to chronic cough, BLU-5937 may potentially have clinical benefit in other afferent hypersensitization-related disorders, such as visceral pain, hypertension, and migraine, among others. BELLUS Health is currently conducting preclinical studies in additional undisclosed indications.

Chronic cough is classified as a cough lasting more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on health and quality-of-life. More than 26 million adults in the United States suffer from chronic cough. Of these patients, more than 2.6 million have unexplained or refractory chronic cough lasting for more than a year. There are currently no approved therapeutics for the treatment of chronic cough.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks factors include but are not limited to: the ability to expand and develop its project pipeline, the ability to obtain financing, the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights, achievement of forecasted pre-clinical and clinical trial milestones and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health Inc.’s product candidates’ development process, their market size and commercial value, as well as the sharing of proceeds between BELLUS Health Inc. and its potential partners from potential future revenues, if any, are dependent upon a number of factors. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health Inc. believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health Inc. is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health Inc.’s public filings with the Canadian securities regulatory authorities, including the Annual Information Form, for further risk factors that might affect BELLUS Health Inc. and its business.

Solebury Trout 
Chad Rubin 

Solebury Trout 
Joshua R Mansbach 

Source: BELLUS Health Inc.